These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18208793)

  • 1. Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
    Jimeno A; Grávalos C; Escudero P; Sevilla I; Vega-Villegas ME; Alonso V; Juez I; García-Carbonero R; Bovio H; Colomer R; Cortés-Funes H
    Clin Transl Oncol; 2008 Jan; 10(1):52-7. PubMed ID: 18208793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
    Laheru D; Croghan G; Bukowski R; Rudek M; Messersmith W; Erlichman C; Pelley R; Jimeno A; Donehower R; Boni J; Abbas R; Martins P; Zacharchuk C; Hidalgo M
    Clin Cancer Res; 2008 Sep; 14(17):5602-9. PubMed ID: 18765554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
    Lam ET; O'Bryant CL; Basche M; Gustafson DL; Serkova N; Baron A; Holden SN; Dancey J; Eckhardt SG; Gore L
    Mol Cancer Ther; 2008 Dec; 7(12):3685-94. PubMed ID: 19074845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Trarbach T; Reinacher-Schick A; Hegewisch-Becker S; Vanhoefer U; Frieling T; Lehnert L; Schmiegel W; Graeven U
    Onkologie; 2010; 33(3):89-93. PubMed ID: 20215798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
    Gelibter AJ; Gamucci T; Pollera CF; Di Costanzo F; Nuzzo C; Gabriele A; Signorelli C; Gasperoni S; Ferraresi V; Giannarelli D; Cognetti F; Zeuli M
    Curr Med Res Opin; 2007 Sep; 23(9):2117-23. PubMed ID: 17651538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.
    Mayer EL; Partridge AH; Harris LN; Gelman RS; Schumer ST; Burstein HJ; Winer EP
    Breast Cancer Res Treat; 2009 Oct; 117(3):615-23. PubMed ID: 19294501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
    Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
    Cabebe EC; Fisher GA; Sikic BI
    Invest New Drugs; 2012 Jun; 30(3):1082-7. PubMed ID: 21404105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
    Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
    Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
    Chu QS; Schwartz G; de Bono J; Smith DA; Koch KM; Versola MJ; Pandite L; Arya N; Curtright J; Fleming RA; Ho PT; Rowinsky EK
    J Clin Oncol; 2007 Aug; 25(24):3753-8. PubMed ID: 17704424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.
    Isakoff SJ; Wang D; Campone M; Calles A; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Calvo E
    Br J Cancer; 2014 Nov; 111(11):2058-66. PubMed ID: 25290090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
    Bajetta E; Di Bartolomeo M; Buzzoni R; Ferrario E; Dotti KF; Mariani L; Bajetta R; Gevorgyan A; Venturino P; Galassi M
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):67-72. PubMed ID: 18936940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
    Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
    Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
    Tewes M; Schleucher N; Achterrath W; Wilke HJ; Frings S; Seeber S; Harstrick A; Rustum YM; Vanhoefer U
    Ann Oncol; 2003 Sep; 14(9):1442-8. PubMed ID: 12954586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
    Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
    J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.